Gilead has agreed to pay $97 million to settle claims that it violated the False Claims Act by using a charitable foundation to …
As the S&P 500 tumbled 15% over the past two months, shares of biotech Gilead Sciences (GILD) went in a somewhat different direction: …
Gilead Sciences, Inc. (NASDAQ:GILD), which built its reputation on turning HIV drug cocktails into easy-to-use, daily, single-pill regimens, announced today that the FDA has approved …
Oppenheimer’s Hartaj Singh notes that Gilead outperformed his 4Q expectations, but continues to play it safe on the giant.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) announced this morning the exclusive US launch of Viread®1 (tenofovir disoproxil fumarate) tablets 300 mg, a generic …
Though Yescarta launch has seen patients condemned to waiting lists, Maxim’s Jason Kolbert is “inspired” by GILD’s global plan to commercialize the drug.
Why this Wall Street hedge fund legend sold VRX and GILD?
ASH data offers insight into Gilead Sciences’ lymphoma drug Yescarta; Maxim’s Jason McCarth weighs in.
Maxim’s McCarthy now sees 27% upside potential for Gilead, impressed with management’s plans for lymphoma asset Yescarta.